uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för radiologi, onkologi och strålningsvetenskap, Enheten för radiologi.
Vise andre og tillknytning
2014 (engelsk)Inngår i: Cancer Metastasis Review, ISSN 0167-7659, E-ISSN 1573-7233, Vol. 33, nr 1, s. 353-359Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

This paper summarizes the current understanding of the biology of somatostatin receptor (sst), role of immunotherapy in neuroendocrine tumor (NET), new agents for PPRT, and methods to assess response and clinical benefit in NET. One of the most interesting aspects of sst biology is the recent discovery of truncated variants of the sst5 receptor subtype with unique tissue distribution and response to somatostatin (SST). These truncated receptors are associated with bad patient prognosis, decreased response to SST analogs, and may be new targets for diagnoses and treatment. IFN remains a cost-effective agent, particularly in classic mid gut carcinoids, and there is interest to continue examining immunotherapy's in this disease. PRRT remains a key strategy for treatment and imaging. In addition to the classic agents, there are a series of new agents targeting other receptors such as the incretin receptors (GLP-1R; GIPR) and other G-protein coupled receptors with great potential. With regards to therapy monitoring, the most commonly used criteria are Response Criteria Evaluation in Solid Tumors (RECIST). However, for different reasons, these criteria are not very useful in NET. Incorporation of other criteria such as Choi as well as functional imaging assessment with PET would be of great interest in this area.

sted, utgiver, år, opplag, sider
2014. Vol. 33, nr 1, s. 353-359
Emneord [en]
Somatostatin, Somatostatin receptor, Splicing, sst5TMD4, Interferon (IFN), Peptide receptor radionucleotide therapy (PRRT), Incretin receptor (GLP-1R, GIPR), RECIST, SWOG, WHO criteria, Functional NET imaging, PET
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-228206DOI: 10.1007/s10555-013-9465-1ISI: 000334423700021OAI: oai:DiVA.org:uu-228206DiVA, id: diva2:733020
Tilgjengelig fra: 2014-07-07 Laget: 2014-07-07 Sist oppdatert: 2017-12-05bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Personposter BETA

Sundin, AndersÖberg, Kjell

Søk i DiVA

Av forfatter/redaktør
Sundin, AndersÖberg, Kjell
Av organisasjonen
I samme tidsskrift
Cancer Metastasis Review

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 966 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf